Highlights & Basics
- Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe skin detachments with mucocutaneous complications associated with a history of medication use, most commonly anticonvulsants, antibiotics, and nonsteroidal anti-inflammatory drugs.
- Patients with HIV or active cancer are at an increased risk of SJS/TEN.
- SJS/TEN may present with mild symptoms in early disease, but the condition progresses over several days; close monitoring and regular reassessment is essential.
- Once a diagnosis is established, the causative agent should be identified and withdrawn; the patient should receive skin care and supportive management.
- Transfer to a burn center, a specialized wound care center, or a dermatology intensive care unit is recommended for patients diagnosed with SJS/TEN.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Citations
Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993 Jan;129(1):92-6.[Abstract]
Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016 Jun;174(6):1194-227.[Abstract][Full Text]
Seminario-Vidal L, Kroshinsky D, Malachowski SJ, et al. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. J Am Acad Dermatol. 2020 Jun;82(6):1553-67.[Abstract]
Gregory DG. New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 2016 Aug;123(8):1653-8.[Abstract]
1. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia. Am J Dis Child. 1922 Dec;24(6):526-33.
2. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015 Dec;16(6):475-93.[Abstract]
3. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993 Jan;129(1):92-6.[Abstract]
4. Charlton OA, Harris V, Phan K, et al. Toxic epidermal necrolysis and Steven-Johnson syndrome: a comprehensive review. Adv Wound Care (New Rochelle). 2020 Jul;9(7):426-39.[Abstract][Full Text]
5. Hsu DY, Brieva J, Silverberg NB, et al. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017 May;76(5):811-7.[Abstract][Full Text]
6. Frey N, Jossi J, Bodmer M, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. J Invest Dermatol. 2017 Jun;137(6):1240-7.[Abstract][Full Text]
7. Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013 May;133(5):1197-204.[Abstract][Full Text]
8. Gillis NK, Hicks JK, Bell GC, et al. Incidence and triggers of Stevens-Johnson syndrome and toxic epidermal necrolysis in a large cancer patient cohort. J Invest Dermatol. 2017 Sep;137(9):2021-3.[Abstract][Full Text]
9. Coopman SA, Johnson RA, Platt R, et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993 Jun 10;328(23):1670-4.[Abstract][Full Text]
10. Mittmann N, Knowles SR, Koo M, et al. Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. Am J Clin Dermatol. 2012 Feb 1;13(1):49-54.[Abstract]
11. Yip VL, Alfirevic A, Pirmohamed M. Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review. Clin Rev Allergy Immunol. 2015 Jun;48(2-3):165-75.[Abstract]
12. Chang CC, Too CL, Murad S, et al. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol. 2011 Feb;50(2):221-4.[Abstract]
13. Chung WH, Hung SI. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis. Allergol Int. 2010 Dec;59(4):325-32.[Abstract][Full Text]
14. Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013 Sep;94(3):324-8.[Abstract][Full Text]
15. Ueta M, Sawai H, Sotozono C, et al. IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. J Allergy Clin Immunol. 2015 Jun;135(6):1538-45.[Abstract]
16. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013 Feb;93(2):153-8.[Abstract][Full Text]
17. Kongpan T, Mahasirimongkol S, Konyoung P, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics. 2015 Aug;25(8):402-11.[Abstract]
18. Tangamornsuksan W, Lohitnavy O, Kongkaew C, et al. Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis. J Pharm Pharm Sci. 2015;18(1):68-76.[Abstract][Full Text]
19. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994 Nov 10;331(19):1272-85.[Abstract]
20. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002 Aug;138(8):1019-24.[Abstract]
21. Nethercott JR, Choi BC. Erythema multiforme (Stevens Johnson syndrome) chart review of 123 hospitalized patients. Dermatologica. 1985;171(6):383-96.[Abstract]
22. Centers for Disease Control and Prevention. Smallpox: vaccine adverse events. 2016 [internet publication].[Full Text]
23. Morantz C. CDC releases guidelines for treating adverse reactions to smallpox vaccination. Am Fam Physician. 2003 Apr 15;67(8):1827, 1829-30.[Abstract][Full Text]
24. Mockenhaupt M. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Semin Cutan Med Surg. 2014 Mar;33(1):10-6.[Abstract]
25. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995 Dec 14;333(24):1600-7.[Abstract][Full Text]
26. Calabrese JR, Sullivan JR, Bowden CL, et al. Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. J Clin Psychiatry. 2002 Nov;63(11):1012-9.[Abstract]
27. Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. 2009 Feb;123(2):e297-304.[Abstract]
28. Rotunda A, Hirsch RJ, Scheinfeld N, et al. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83(1):1-9.[Abstract]
29. Borras-Blasco J, Navarro-Ruiz A, Borras C, et al. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother. 2008 Nov;62(5):879-88.[Abstract][Full Text]
30. La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf. 2005;28(10):917-24.[Abstract]
31. Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf. 2006;29(8):687-96.[Abstract]
32. Roujeau JC, Mockenhaupt M, Tahan SR, et al. Telaprevir-related dermatitis. JAMA Dermatol. 2013 Feb;149(2):152-8.[Abstract][Full Text]
33. Mufaddel A, Osman OT, Almugaddam F. Adverse cutaneous effects of psychotropic medications. Exp Rev Dermatol. 2013;8(6):681-92.
34. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. J Invest Dermatol. 2008 Jan;128(1):35-44.[Abstract][Full Text]
35. Irazabal MP, Martin LM, Gil LA, et al. Tranexamic acid-induced toxic epidermal necrolysis. Ann Pharmacother. 2013 Mar;47(3):e16.[Abstract]
36. Tremblay L, de Chambrun GP, De Vroey B, et al. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J Crohns Colitis. 2011 Oct;5(5):457-60.[Abstract][Full Text]
37. Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014 Feb;25(2):225-34.[Abstract][Full Text]
38. Mawson AR, Eriator I, Karre S. Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN): could retinoids play a causative role? Med Sci Monit. 2015 Jan 12;21:133-43.[Abstract][Full Text]
39. Chen CB, Wu MY, Ng CY, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018;10:1259-73.[Abstract][Full Text]
40. Paul C, Wolkenstein PC, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996 Apr;134(4):710-4.[Abstract]
41. Le Cleach L, Delaire S, Boumsell L, et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol. 2000 Jan;119(1):225-30.[Abstract][Full Text]
42. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part I: introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013 Aug;69(2):173.[Abstract]
43. Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 2006 Oct;155(4):722-8.[Abstract]
44. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis. Part II: prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol. 2013 Aug;69(2):187.[Abstract]
45. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998 Oct 16;282(5388):490-3.[Abstract]
46. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008 Dec;14(12):1343-50.[Abstract]
47. Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003 May;162(5):1515-20.[Abstract][Full Text]
48. Hama N, Nishimura K, Hasegawa A, et al. Galectin-7 as a potential biomarker of Stevens-Johnson syndrome/toxic epidermal necrolysis: identification by targeted proteomics using causative drug-exposed peripheral blood cells. J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2894-7.[Abstract]
49. Hasegawa A, Shinkuma S, Hayashi R, et al. RIP3 as a diagnostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol Pract. 2020 May;8(5):1768-71.[Abstract]
50. Ziemer M, Kardaun SH, Liss Y, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. Br J Dermatol. 2012 Mar;166(3):575-600.[Abstract]
51. Vern-Gross TZ, Kowal-Vern A. Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review. Am J Clin Oncol. 2014 Oct;37(5):506-13.[Abstract]
52. Demiral AN, Yerebakan O, Simsir V, et al. Amifostine-induced toxic epidermal necrolysis during radiotherapy: a case report. Jpn J Clin Oncol. 2002 Nov;32(11):477-9.[Abstract][Full Text]
53. Jorge J, Kowal-Vern A, Fung HCH, et al. Toxic epidermal necrolysis and graft versus host disease after hematopoietic and liver transplantation: a review. Int J Clin Expl Dermatol. 2018 Sep 27;3(1):1-9.[Full Text]
54. de Prost N, Mekontso-Dessap A, Valeyrie-Allanore L, et al. Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. Crit Care Med. 2014 Jan;42(1):118-28.[Abstract]
55. Lund CC, Browder NC. The estimation of areas of burns. Surg Gynecol Obst. 1944;79:352-8.
56. Hettiaratchy S, Papini R. Initial management of a major burn: II - assessment and resuscitation. BMJ. 2004 Jul 10;329(7457):101-3.[Abstract][Full Text]
57. Wachtel TL, Berry CC, Wachtel EE, et al. The inter-rater reliability of estimating the size of burns from various burn area chart drawings. Burns. 2000 Mar;26(2):156-70.[Abstract]
58. Sekula P, Liss Y, Davidovici B, et al. Evaluation of SCORTEN on a cohort of patients with Stevens-Johnson Syndrome and toxic epidermal necrolysis included in the RegiSCAR study. J Burn Care Res. 2011 Mar-Apr;32(2):237-45.[Abstract]
59. Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006 Feb;126(2):272-6.[Abstract][Full Text]
60. Cartotto R, Mayich M, Nickerson D, et al. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res. 2008 Jan-Feb;29(1):141-6.[Abstract]
61. George SM, Harrison DA, Welch CA, et al. Dermatological conditions in intensive care: a secondary analysis of the Intensive Care National Audit and Research Centre (ICNARC) case mix programme database. Crit Care. 2008;12(suppl 1):S1.[Abstract][Full Text]
62. Imahara SD, Holmes JH, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res. 2006 May-Jun;27(3):270-5.[Abstract]
63. Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016 Jun;174(6):1194-227.[Abstract][Full Text]
64. American Society for Clinical Pathology. Thirty five things physicians and patients should question. Choosing Wisely, an initiative of the ABIM Foundation. 2021 [internet publication].[Full Text]
65. Kowal-Vern A, Walenga JW, Hoppensteadt D, et al. Patients with Stevens-Johnson syndrome and toxic epidermal necrolysis develop coagulopathies similar to those seen in burn patients: a pilot study. Int J Clin Expl Dermatol. 2018 Sep 27;3(1):1-9.[Full Text]
66. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol. 2013 May;68(5):693.[Abstract]
67. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part II. Management and therapeutics. J Am Acad Dermatol. 2013 May;68(5):709.[Abstract]
68. Baba M, Karakas M, Aksunger VL, et al. The anticonvulsant hypersensitivity syndrome. J Eur Acad Dermatol Venereol. 2003 Jul;17(4):399-401.[Abstract]
69. Centers for Disease Control and Prevention. Toxic syndrome description: vesicant/blister agent poisoning. Apr 2018 [internet publication].[Full Text]
70. Sehgal V, Srivastava G. Fixed drug eruption (FDE): changing scenario of incriminating drugs. Int J Dermatol. 2006 Aug;45(8):897-908.[Abstract]
71. Lipowicz S, Sekula P, Ingen-Housz-Oro S, et al. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2013 Apr;168(4):726-32.[Abstract]
72. Thienvibul C, Vachiramon V, Chanprapaph K. Five-year retrospective review of acute generalized exanthematous pustulosis. Dermatol Res Pract. 2015;2015:260928.[Abstract][Full Text]
73. Chung WH, Shih SR, Chang CF, et al. Clinicopathologic analysis of coxsackievirus A6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions. J Infect Dis. 2013 Dec 15;208(12):1968-78.[Abstract][Full Text]
74. Garg T, Sanke S, Ahmed R, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis-like cutaneous presentation of chikungunya fever: a case series. Pediatr Dermatol. 2018 May;35(3):392-6.[Abstract]
75. Seminario-Vidal L, Kroshinsky D, Malachowski SJ, et al. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. J Am Acad Dermatol. 2020 Jun;82(6):1553-67.[Abstract]
76. Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017 Jun 1;153(6):514-22.[Abstract][Full Text]
77. Schneider JA, Cohen PR. Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther. 2017 Jun;34(6):1235-44.[Abstract][Full Text]
78. Nizamoglu M, Ward JA, Frew Q, et al. Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: a regional burns centre experience. Burns. 2018 May;44(3):603-11.[Abstract]
79. Shiga S, Cartotto R. What are the fluid requirements in toxic epidermal necrolysis? J Burn Care Res. 2010 Jan-Feb;31(1):100-4.[Abstract]
80. Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol. 2015 Jan;54(1):108-15.[Abstract]
81. Aires DJ, Fraga G, Korentager R, et al. Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality. J Drugs Dermatol. 2013 Jun 1;12(6):679-84.[Abstract]
82. Enk A, Hadaschik E, Eming R, et al. European guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. J Dtsch Dermatol Ges. 2017 Feb;15(2):228-41.[Abstract]
83. Kirchhof MG, Miliszewski MA, Sikora S, et al. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol. 2014 Nov;71(5):941-7.[Abstract]
84. Balai M, Meena M, Mittal A, et al. Cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis: experience from a tertiary care centre of South Rajasthan. Indian Dermatol Online J. 2021 Jan-Feb;12(1):116-22.[Abstract][Full Text]
85. Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010 Oct;163(4):847-53.[Abstract]
86. Ng QX, De Deyn MLZQ, Venkatanarayanan N, et al. A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis. J Inflamm Res. 2018 Mar 28;11:135-42.[Abstract][Full Text]
87. González-Herrada C, Rodríguez-Martín S, Cachafeiro L, et al. Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol. 2017 Oct;137(10):2092-100.[Abstract][Full Text]
88. Roujeau JC, Mockenhaupt M, Guillaume JC, et al. New evidence supporting cyclosporine efficacy in epidermal necrolysis. J Invest Dermatol. 2017 Oct;137(10):2047-9.[Abstract][Full Text]
89. Gregory DG. New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 2016 Aug;123(8):1653-8.[Abstract]
90. Van Batavia JP, Chu DI, Long CJ, et al. Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Pediatr Urol. 2017 Oct;13(5):490.e1-7.[Abstract]
91. Meneux E, Wolkenstein P, Haddad B, et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol. 1998 Feb;91(2):283-7.[Abstract]
92. Gupta LK, Martin AM, Agarwal N, et al. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: an Indian perspective. Indian J Dermatol Venereol Leprol. 2016 Nov-Dec;82(6):603-25.[Abstract][Full Text]
93. Zhang S, Tang S, Li S, et al. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. J Dermatolog Treat. 2020 Feb;31(1):66-73.[Abstract]
94. Paradisi A, Abeni D, Didona D, et al. A new case series on etanercept treatment for toxic epidermal necrolysis. Eur J Dermatol. 2020 Oct 1;30(5):561-8.[Abstract]
95. Zhang J, Lu CW, Chen CB, et al. Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: a multicenter observational study. J Allergy Clin Immunol Pract. 2022 May;10(5):1295-304.[Abstract]
96. Satake Y, Higa K, Tsubota K, et al. Long-term outcome of cultivated oral mucosal epithelial sheet transplantation in treatment of total limbal stem cell deficiency. Ophthalmology. 2011 Aug;118(8):1524-30.[Abstract]
97. Sotozono C, Inatomi T, Nakamura T, et al. Cultivated oral mucosal epithelial transplantation for persistent epithelial defect in severe ocular surface diseases with acute inflammatory activity. Acta Ophthalmol. 2014 Sep;92(6):e447-53.[Abstract][Full Text]
98. American Academy of Ophthalmology; Slentz DH, Hemmati HD. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis. EyeNet. December 2013 [internet publication].[Full Text]
99. McPherson T, Exton LS, Biswas S, et al. British Association of Dermatologists' guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018. Br J Dermatol. 2019 Jul;181(1):37-54.[Abstract][Full Text]
100. Finkelstein Y, Soon GS, Acuna P, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011 Oct;128(4):723-8.[Abstract]
101. Del Pozzo-Magaña BR, Lazo-Langner A. Stevens Johnson Syndrome and toxic epidermal necrolysis in children: a literature review of current treatments. EMJ Dermatol. 2016 Nov;4(1):83-9.[Full Text]
102. Singalavanija S, Limpongsanurak W. Stevens-Johnson syndrome in Thai children: a 29-year study. J Med Assoc Thai. 2011 Aug;94(suppl 3):S85-90.[Abstract]
103. Palmieri TL, Greenhalgh DG, Saffle JR, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil. 2002 Mar-Apr;23(2):87-96.[Abstract]
104. Wakamatsu TH, Ueta M, Tokunaga K, et al. Human leukocyte antigen class I genes associated with Stevens-Johnson syndrome and severe ocular complications following use of cold medicine in a Brazilian population. JAMA Ophthalmol. 2017 Apr 1;135(4):355-60.[Abstract][Full Text]
105. Jeschke MG, Finnerty CC. The hepatic response to a thermal injury. In: Herndon DN, ed. Total burn care. 4th ed. Philadelphia, PA: Elsevier; 2012:301-12.
106. Goverman J, Fagan SP. Renal failure in association with thermal injuries. In: Herndon, DN, ed. Total burn care. 4th ed. Philadelphia, PA: Elsevier; 2012:369-76.
107. Kaser DJ, Reichman DE, Laufer MR. Prevention of vulvovaginal sequelae in Stevens-Johnson syndrome and toxic epidermal necrolysis. Rev Obstet Gynecol. 2011 Summer;4(2):81-5.[Full Text]
108. Kamada N, Kinoshita K, Togawa Y, et al. Chronic pulmonary complications associated with toxic epidermal necrolysis: report of a severe case with anti-Ro/SS-A and a review of the published work. J Dermatol. 2006 Sep;33(9):616-22.[Abstract]
109. Baccaro LM, Sakharpe A, Miller A, et al. The first reported case of ureteral perforation in a patient with severe toxic epidermal necrolysis syndrome. J Burn Care Res. 2014 Jul-Aug;35(4):e265-8.[Abstract]
110. Kamal T, Elnikety S, Mashaly H, et al. Acute compartment syndrome of the forearm as a rare complication of toxic epidermal necrolysis: a case report. J Med Case Rep. 2012 Mar 20;6:84.[Abstract][Full Text]
111. Maverakis E, Wang EA, Shinkai K, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis standard reporting and evaluation guidelines: results of a National Institutes of Health Working Group. JAMA Dermatol. 2017 Jun 1;153(6):587-92.[Abstract]
